ALS clinical trials: Do enrolled patients accurately represent the ALS population?

Neurology

Volumn 77, Issue 15, 2011, Pages 1432-1437

  Chio A ^a   Canosa, A ^a   Gallo, S ^a   Cammarosano, S ^a   Moglia, C ^a   Fuda, G ^a   Calvo, A ^a   Mora, G ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RILUZOLE;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; DISEASE DURATION; DYSPHAGIA; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RESPIRATORY FAILURE; SURVIVAL; TRACHEOSTOMY;

EID: 82955167994     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e318232ab9b     Document Type: Article

References (25)

1. Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev 2007;1:CD001447.
2. Beghi E, Chiò A, Couratier P, et al. The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler 2011;12:1-10.
3. Bento-Abreu A, Van Damme P, Van Den Bosch L, Robberecht W. The neurobiology of amyotrophic lateral sclerosis. Eur J Neurosci 2010;31:2247-2265.
4. Ludolph AC, Bendotti C, Blaugrund E, et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler 2010;11:38-45.
5. Chiò A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry Epub 2011 Mar 14.
6. Sanjak M, Salachas F, Frija-Orvoen E, et al. Quality control of vital capacity as a primary outcome measure during phase III therapeutic clinical trial in amyotrophic lateral sclerosis. Amyotroph Lateral Scler 2010;11:383-388.
7. Olanow CW, Kieburz K, Shapira AHV. Why we have failed to achieve neuroprotection in Parkinson's disease? Ann Neurol 2008;64(suppl):S101-S110.
8. Miller R, Bradley W, Cudkowicz M, et al. Phase II/III randomized trial of TCH346 in patients with ALS. Neurology 2007;9:776-784. (Pubitemid 47300935)
9. Meininger V, Drory VE, Leigh PN, Ludolph A, Robberecht W, Silani V. Glatiramer acetate has no impact on disease progression in ALS at 40 mg/day: A double-blind, randomized, multicentre, placebo-controlled trial. Amyotroph Lateral Scler 2009;10:378-383.
10. Tarella C, Rutella S, Gualandi F, et al. Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte-colony- stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicentre prospective trial. Cytotherapy 2010; 12:50-59.
11. Chiò A, Mora G, Bella VL, et al. Repeated courses of granulocyte colony-stimulating factor in amyotrophic lateral sclerosis: Clinical and biological results from a prospective multicentre study. Muscle Nerve 2011;43:189-195.
12. Chiò A, Borghero G, Calvo A, et al. Lithium carbonate in amyotrophic lateral sclerosis: lack of efficacy in a dosefinding trial. Neurology 2010;75:619-625.
13. Chiò A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology 2009;72:725-731.
14. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000;57: 1171-1176. (Pubitemid 30644664)
15. Zoccolella S, Beghi E, Palagano G, et al. Predictors of delay in the diagnosis and clinical trial entry of amyotrophic lateral sclerosis patients: a population-based study. J Neurol Sci 2006;250:45-49. (Pubitemid 44679704)
16. O'Toole O, Traynor BJ, Brennan P, et al. Epidemiology and clinical features of amyotrophic lateral sclerosis in Ireland between 1995 and 2004. J Neurol Neurosurg Psychiatry 2008;79:30-32.
17. Ringel SP, Murphy JR, Alderson MK, et al. The natural history of amyotrophic lateral sclerosis. Neurology 1993; 43:1316-1322. (Pubitemid 23213802)
18. Lee JR, Annegers JF, Appel SH. Prognosis of amyotrophic lateral sclerosis and the effect of referral selection. J Neurol Sci 1995;132:207-215.
19. Manjaly ZR, Scott KM, Abhinav K, et al. The sex ratio in amyotrophic lateral sclerosis: A population based study. Amyotroph Lateral Scler 2010;11:439-442.
20. Traynor BJ, Alexander M, Corr B, Frost E, Hardiman O. Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000. J Neurol Neurosurg Psychiatry 2003;74:1258-1261.
21. Chiò A, Bottacchi E, Buffa C, Mutani R, Mora G. PARALS: positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities. J Neurol Neurosurg Psychiatry 2006;77:948-950. (Pubitemid 44174080)
22. Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA 2004;291:2720-2726. (Pubitemid 38725421)
23. Mosenifar Z. Population issues in clinical trials. Proc Am Thorac Soc 2007;4:185-187. (Pubitemid 46743316)
24. Chiò A, Calvo A, Ghiglione P, Mazzini L, Mutani R, Mora G, for PARALS. Tracheostomy in amyotrophic lateral sclerosis: a 10-year population-based study in Italy. J Neurol Neurosurg Psychiatry 2010;81:1141-1143.
25. Baquet CR, Commiskey P, Daniel Mullins C, Mishra SI. Recruitment and participation in clinical trials: sociodemographic, rural/urban, and health care access predictors. Cancer Detect Prev 2006;30:24-33. (Pubitemid 43374500)